8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 2, 2011)

Filed February 2, 2011For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on February 2, 2011, to report its financial results for the fourth quarter and full year ended December 31, 2010. The filing itself is brief, primarily referencing an attached press release (Exhibit 99.1) which contains the detailed financial performance information. Investors should refer to this press release for specific revenue, profit, and guidance figures. This report signals a routine update on the company's operational and financial standing. The significance for investors lies in the performance metrics revealed in the press release, which would indicate trends in sales, profitability, and potentially future outlook for Edwards Lifesciences, a key player in the medical device sector, particularly in cardiovascular and critical care technologies.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on February 2, 2011.
  • 2The filing reports financial results for the fourth quarter and full year 2010.
  • 3The detailed financial results are provided in an attached press release (Exhibit 99.1).
  • 4The report confirms the company's adherence to public disclosure requirements for financial performance.
  • 5No other material events requiring immediate disclosure under other 8-K items were reported.
  • 6Thomas M. Abate, Corporate Vice President and Chief Financial Officer, signed the report.
  • 7The filing was made to satisfy reporting obligations under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report Edwards Lifesciences Corporation's financial results for the fourth quarter and the full fiscal year 2010. It serves as a formal disclosure to the SEC and the investing public.

The detailed financial results, including revenue, net income, and potentially earnings per share for the fourth quarter and full year 2010, are contained within the press release attached as Exhibit 99.1 to this 8-K filing.

This specific 8-K filing, based on the provided text, focuses solely on the disclosure of financial results. It does not appear to report any new material events, risks, or other significant corporate changes outside of the routine financial reporting.

The report was signed by Thomas M. Abate, who serves as the Corporate Vice President and Chief Financial Officer of Edwards Lifesciences Corporation.